Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Dipeptidase-IV inhibitor compound

A compound and composition technology, applied in the field of medicine, can solve the problems of not meeting clinical needs, limited variety of DPP-IV inhibitors, etc.

Active Publication Date: 2009-02-04
BEIJING AOHE DRUG RES INST
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The variety of DPP-IV inhibitors is limited and cannot meet the clinical needs, and there is an urgent need to develop more DPP-IV inhibitor drugs to meet the clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dipeptidase-IV inhibitor compound
  • Dipeptidase-IV inhibitor compound
  • Dipeptidase-IV inhibitor compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0146] Example 1 (2R, 5S)-2,5-dihydro-3,6-dimethoxy-2-[bis(4-fluoro-phenyl)]methyl]-5-isopropylpyrazine preparation

[0147]18.4g (100mmol) (2S)-(+)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine was dissolved in 400ml tetrahydrofuran, and then heated at -78°C for 30min Add dropwise 48ml (120mmol, 2.5N) of n-butyllithium / n-hexane solution, keep stirring for 30min, then dropwise add 26.3g (110mmol) of 4-fluoro-diphenylchloromethane in 50ml of tetrahydrofuran cold solution, -78°C Stir the reaction for 5h, add 100ml of water at -78°C to quench the reaction, concentrate the reaction solution, partition the residue between ethyl acetate and 1N hydrochloric acid, extract the aqueous layer three times with ethyl acetate, combine the organic layers, wash with salt, and anhydrous Dry over magnesium sulfate, concentrate under reduced pressure, and purify on a silica gel column (ethyl acetate:cyclohexane=1:20~1:10) to obtain 26.8 g of the target compound as colloidal solid, yield: 69.4...

Embodiment 2

[0148] Example 2 Preparation of (R)-N-2-(tert-butoxycarbonyl)-3,3-bis(4-fluorophenyl)alanine methyl ester

[0149] 38.6g (100mmol) of (2R,5S)-2,5-dihydro-3,6-dimethoxy-2-[bis(4-fluoro-phenyl)]methyl]-5-isopropyl Dissolve pyrazine in 200ml of acetonitrile, then add 200ml of 1N hydrochloric acid dropwise, stir the reaction solution at room temperature for 24 hours, add methanol, concentrate to dryness, repeat this operation three times, and then repeat it once with toluene to obtain a solid, which is treated with 700ml of dichloro Add 100g triethylamine after the methane dissolves, then add 52.3g (231.1mmol) (Boc) dropwise 2 O, the reaction solution was stirred at room temperature for 8 h, the solid generated by the reaction was filtered off, the filtrate was diluted with dichloromethane, washed with 1N HCl solution and saturated brine respectively, dried over anhydrous magnesium sulfate, purified on a silica gel column, and the eluents were acetonitrile and petroleum ether (...

Embodiment 3

[0150] Example 3 Preparation of (R)-N-2-(tert-butoxycarbonyl)-3,3-bis(4-fluorophenyl)alanine

[0151] Add 300ml tetrahydrofuran to 23.5g (60mmol) of (R)-N-2-(tert-butoxycarbonyl)-3,3-bis(4-fluorophenyl)alanine methyl ester, cool in an ice bath, and then dropwise add 4.12g (172.3mmol) 200ml aqueous solution of lithium hydroxide, the reaction solution was stirred at room temperature for 15h, concentrated under reduced pressure, the residue was dissolved in ethyl acetate, washed with saturated sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and evaporated to obtain 18g Solid, yield: 79.3%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the medicine technology field, which more particularly relates to a dipeptidase-IV inhibitor compound, the salt acceptable in pharmacy and the isomer thereof shown in the formula (I); wherein, the Ar, Ar', X, and R<1> are defined in an introduction; The invention also relates to preparing methods of the compounds, the drug combination containing the compounds and the applications of the compounds in preparing the medicine for curing or preventing diabetes, non-insulin-dependent diabetes, hyperglycemia and insulin resistance.

Description

1. Technical field [0001] The present invention belongs to the technical field of medicine, and specifically relates to dipeptidase-IV (DPP-IV) inhibitor compounds, pharmaceutically acceptable salts and isomers thereof, preparation methods of these compounds, pharmaceutical compositions containing these compounds, And the application of these compounds in the preparation of medicines for treating and / or preventing diabetes, non-insulin-dependent diabetes, hyperglycemia and insulin resistance. 2. Background technology [0002] Diabetes is a systemic chronic metabolic disease caused by uncontrolled blood sugar levels higher than normal. Basically divided into four categories, including: type I (insulin-dependent), type II (non-insulin-dependent), other types and gestational diabetes. Type 1 and type 2 diabetes belong to primary diabetes, the two most common forms, caused by the interaction of genetic and environmental factors. The etiology of diabetes is very complex, but in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04A61K31/4985A61P3/10
Inventor 黄振华赵红宇
Owner BEIJING AOHE DRUG RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com